אבילק סירופ ישראל - עברית - Ministry of Health

אבילק סירופ

padagis israel pharmaceuticals ltd, israel - lactulose - סירופ - lactulose 66.7 g / 100 ml - lactulose - lactulose - constipation. acute and chronic hepatic encephalopathy.

לבולק ישראל - עברית - Ministry of Health

לבולק

megapharm ltd - lactulose - תמיסה (פומי) - lactulose 670 mg/ml - lactulose - lactulose - constipation. acute and chronic hepatic encephalopathy.

נורמס ישראל - עברית - Ministry of Health

נורמס

bioavenir ltd - lactulose 66.7 g / 100 ml - solution (oral) - lactulose - chronic constipation. acute and chronic hepatic encephalopathy.

נורמס ישראל - עברית - Ministry of Health

נורמס

bioavenir ltd - lactulose 66.7 g / 100 ml - solution (oral) - lactulose - chronic constipation. acute and chronic hepatic encephalopathy.

Care beds,mobile patients hoists,antidecubitus foam mattresses ישראל - עברית - Ministry of Health

care beds,mobile patients hoists,antidecubitus foam mattresses

קוסמוטרייד(1987) בע"מ - אחות - מיטות סיעודיות, מתקני הרמת חולה ואביזרים

ספראבטו ישראל - עברית - Ministry of Health

ספראבטו

j-c health care ltd - esketamine as hydrochloride - esketamine as hydrochloride 28 mg/vial - esketamine

לורמיקס 200 מג ישראל - עברית - Ministry of Health

לורמיקס 200 מג

megapharm ltd - rifaximine - טבליות מצופות פילם - rifaximine 200 mg - rifaximin - rifaximin - • casual treatment of diseases of grown-ups and youngsters from 12 years up, caused by bacteria in the gastrointestinal tract, sensitive to rifaximin:• hepatic encephalopathy • traveller’s diarrhea, caused by not-invasive enteropathogeneous bacteria

ניופוגן 30 MU בקבוקונים ישראל - עברית - Ministry of Health

ניופוגן 30 mu בקבוקונים

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu/ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

ניופוגן MU 48 מזרק מוכן לשימוש ישראל - עברית - Ministry of Health

ניופוגן mu 48 מזרק מוכן לשימוש

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 48 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).

ניופוגן  MU 30 מזרק מוכן לשימוש ישראל - עברית - Ministry of Health

ניופוגן mu 30 מזרק מוכן לשימוש

amgen europe b.v. - filgrastim - תמיסה להזרקה - filgrastim 30 mu / 0.5 ml - filgrastim - filgrastim - - reduction in the duration and severity of neutropenia in patients treated with highly myelosuppressive chemotherapy for malignancy (with the exception of chronic myeloid leukaemia and myelodysplastic syndromes ).- reduction in the duration of neutropenia in patients undergoing high-dose cytotoxic chemotherapy followed by bone marrow transplantation. - in children or adults with severe congenital neutropenia cyclic neutropenia or idiopathic neutropenia a history of clinically important infections within the last 12 months and three documented episodes of neutropenia (with an anc< 5 x 1000000000) long-term administration of neupogen is indicated to increase neutrophil counts and to reduce infections. - neupogen is indicated for the mobilisation of autologous peripheral blood progenitor cells alone or following myelosuppressive chemotherapy and the mobilisation of peripheral blood progenitor cells in normal donors (allogeneic pbpc).